Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod

Neurol Sci. 2023 Jan;44(1):361-363. doi: 10.1007/s10072-022-06367-3. Epub 2022 Aug 29.

Abstract

Primary central nervous system lymphoma (PCNSL) is an uncommon lymphoproliferative disease associated with immunosuppression. Here, we report the case of a patient with multiple sclerosis, under treatment with fingolimod (FTY720, Gilenya) for 4 years, who developed this condition. Although the causal relationship cannot be established, there are cases in the literature that describe the appearance of lymphoma after the use of this medication. Considering the high mortality of PCNSL, epidemiological studies are necessary to establish a relationship between its arising and the use of immunosuppressants.

Keywords: Brain; CNS; Fingolimod; Lymphoma; Multiple sclerosis; Primary.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Central Nervous System / pathology
  • Fingolimod Hydrochloride / adverse effects
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Lymphoma* / chemically induced
  • Lymphoma* / complications
  • Lymphoma* / drug therapy
  • Multiple Sclerosis* / complications
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis* / pathology

Substances

  • Fingolimod Hydrochloride
  • Immunosuppressive Agents